Results 71 to 80 of about 27,256 (249)

Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients [PDF]

, 2016
Aims: Treatment with glucagon-like peptide (GLP)-1 receptor agonists or dipeptidyl peptidase (DPP)-4 inhibitors might increase gallstone formation; however, the mechanisms involved are unknown. We aimed to assess the effects of these drugs on gallbladder
Cahen, D.L. (Djuna), Diamant, M. (Michaela), Groen, A. (Albert), Hoekstra, T. (Trynke), Kramer, M.H.H. (Mark), Muskiet, M.H.A. (Marcel H. A.), Nieuwdorp, M. (Max), Smits, M.M. (Mark M.), Tonneijck, L. (Lennart), van Raalte, D.H. (Daniël H.)   +9 more
core   +1 more source

Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim This study evaluated the efficacy and safety of empagliflozin 10 and 25 mg compared to placebo as add‐on treatment for people with type 2 diabetes mellitus (T2DM) uncontrolled after ≥8 weeks of treatment with metformin and sitagliptin. Materials and Methods A randomised, double‐blind, multicentre, therapeutic confirmatory, phase 3 clinical
Seung‐Hwan Lee, Kyung Ah Han, Eun‐Gyoung Hong, Jun Goo Kang, Choon Hee Chung, Jong Chul Won, Eon Ju Jeon, Jung‐Hwan Cho, Ho Chan Cho, Sin Gon Kim, Eun Seok Kang, So Hun Kim, Hae Jin Kim, In‐Kyung Jeong, Sung Wan Chun, Young Min Cho   +15 more
wiley   +1 more source

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

BMC Endocrine Disorders, 2010
Background In a previous pooled analysis of 12 double-blind clinical studies that included data on 6,139 patients with type 2 diabetes, treatment with sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, was shown to be generally well tolerated ...
Guo Hua, Golm Gregory T, Johnson Jeremy, Round Elizabeth, Engel Samuel S, Williams-Herman Debora, Musser Bret J, Davies Michael J, Kaufman Keith D, Goldstein Barry J   +9 more
doaj   +1 more source

Risk of acute pancreatitis with DPP‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims We investigated whether dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use was associated with a higher risk of acute pancreatitis compared with sodium–glucose cotransporter 2 inhibitor (SGLT2i) use in antidiabetic medication‐naïve individuals.
Takashi Tatewaki, Akira Okada, Yuya Kimura, Hideo Yasunaga   +3 more
wiley   +1 more source

Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes [PDF]

, 2017
Diabetic nephropathy (DN) is now the single commonest cause of end-stage renal disease (ESRD) worldwide and one of the main causes of death in diabetic patients.
Fernandes, Rosa, Lemos, Edite Teixeira de, Mega, Cristina, Reis, Flávio   +3 more
core   +3 more sources

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Toshiyuki Ko, Kazuki Aoyama, Takashin Nakayama, Yuya Kimura, Katsuhiko Fujiu, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Koichi Node, Masaomi Nangaku, Norihiko Takeda, Hideo Yasunaga, Kaori Hayashi   +16 more
wiley   +1 more source

Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial [PDF]

, 2015
Background: Impaired glucose tolerance is present in one third of patients with a TIA or ischemic stroke and is associated with a two-fold risk of recurrent stroke. Metformin improves glucose tolerance, but often leads to side effects.
Brouwers, P.J. (Paul), Dippel, D.W.J. (Diederik), Fonville, S. (Susanne), Hertog, H.M. (Heleen) den, Koudstaal, P.J. (Peter), Lingsma, H.F. (Hester), Mulder, L.J.M.M. (Laus), Osei, E. (Elizabeth), Zandbergen, A.A.M. (Adrienne)   +8 more
core   +1 more source

Uncoupling Protein-2 Mediates DPP-4 Inhibitor-Induced Restoration of Endothelial Function in Hypertension Through Reducing Oxidative Stress [PDF]

, 2014
published_or_final_versio
Gao, Y, Huang, Y, Lau, CW, Liu, J, Liu, L, Ng, CF, Tian, XY, Wong, WT, Xu, A, Xu, G, Yao, X   +10 more
core   +1 more source

GLP‐1 Receptor Agonists for the Prevention of New‐Onset Heart Failure: A Systematic Review and Meta‐Analysis of Placebo‐Controlled Randomized Clinical Trials

Obesity Reviews, EarlyView.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) improve outcomes in heart failure (HF) with preserved ejection fraction. Whether GLP‐1 RA prevent new‐onset HF in Type 2 diabetes or obesity requires further investigation. Methods We performed an updated meta‐analysis of randomized placebo‐controlled trials (RCT) of treatment ...
João Sérgio Neves, Carolina B. Lobato, Ana Rita Leite, Catarina Vale, Francisco Vasques‐Nóvoa, Francisca Saraiva, Adelino Leite‐Moreira, Jens J. Holst, João Pedro Ferreira   +8 more
wiley   +1 more source

Gitelman and Bartter Syndrome in a Patient With Morbid Obesity: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT We present a case study of a 34‐year‐old man with morbid obesity and a suspected Bartter–Gitelman spectrum tubulopathy (without genetic confirmation), weighing 135 kg, and with a BMI of 42.5 kg/m2, who was referred to the metabolic and bariatric surgery department due to morbid obesity to address abnormal electrolyte levels.
Solmaz Hasani, Alireza Rezapanah, Tooraj Zandbaf, Mohammad Javad Ghamari, Narges Mesbah   +4 more
wiley   +1 more source